Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

Rhea-AI Summary

Compugen (NASDAQ: CGEN) will release first quarter 2026 financial results on Monday, May 18, 2026 before U.S. markets open. Management will host a conference call and webcast at 8:30 AM ET to review results and provide a corporate update.

Telephone access: 1-866-744-5399 (U.S.) or +972-3-918-0644 (international). A live webcast and subsequent replay will be available via the company's investor website.

News Market Reaction – CGEN

-2.58%

3 alerts

-2.58% Session close to close

$267.59M Market Cap

0.1x Rel. Volume

In the May 4 session, CGEN declined 2.58%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the schedule for Compugen’s Q1 2026 results and conference call, following st...

Analysis

This announcement sets the schedule for Compugen’s Q1 2026 results and conference call, following strong 2025 figures including $72.8M revenue and $35.3M net income. Historically, similar earnings date notices have led to a modest 1.82% move. Investors may focus on how Q1 results compare with the prior year’s performance, cash position of $145.6M, and any updates on clinical and partnership milestones when the call occurs.

Key Figures

Cash balance: $145.6M AstraZeneca upfront: $65M Cash runway: 2029 +5 more

8 metrics

Cash balance $145.6M Year-end 2025 cash as reported Mar 2, 2026

AstraZeneca upfront $65M Royalty monetization upfront noted in 2025 results

Cash runway 2029 Expected cash runway into 2029 from 2025 results update

2025 revenue $72.8M Full-year 2025 revenue reported Mar 2, 2026

Q4 2025 revenue $67.3M Q4 2025 revenue in 2025 results release

2025 net income $35.3M Full-year 2025 net income

Q4 2025 net profit $56.8M Q4 2025 net profit from 2025 results

Earnings call time 8:30 AM ET Scheduled start of Q1 2026 conference call on May 18, 2026

Previous Earnings date Reports

1 past event · Latest: Feb 17 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 17	Earnings date notice	Neutral	+1.8%	Announcement of Q4 and full-year 2025 earnings release timing and call details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior 'earnings date' scheduling news led to a modest positive move of 1.82%, suggesting these timing announcements have historically had limited but positive impact.

Recent Company History

This announcement schedules Compugen’s Q1 2026 results, similar to the prior notice on Feb 17, 2026 for Q4 and full‑year 2025 results, which preceded a 1.82% gain. Recent history includes strong fundamentals reported on Mar 2, 2026, with cash of $145.6M, $72.8M 2025 revenue, and net income of $35.3M, plus multiple conference participations. Today’s news continues the pattern of regular communication around financial reporting dates.

Key Terms

cancer immunotherapy, computational drug target discovery, ai/ml

3 terms

cancer immunotherapy medical

"Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company"

Cancer immunotherapy is a group of treatments that help the body’s immune system recognize and attack cancer cells, like training the body’s soldiers to spot a hidden enemy. It matters to investors because these therapies can transform patient outcomes and create large markets if shown safe and effective, so clinical trial results, regulatory approvals, and manufacturing scale can drive significant changes in a company’s revenue and stock value.

computational drug target discovery medical

"a pioneer in computational drug target discovery powered by AI/ML"

Using computer models, large biological datasets, and simulations to identify molecules, genes or proteins in the body that a medicine could act on. Think of it as using a powerful search engine and map to pinpoint promising addresses for drug development before lab work begins. For investors, it matters because successful computational discovery can speed development, lower early costs and increase the chance of finding viable drug candidates, though it does not guarantee clinical or regulatory success.

ai/ml technical

"a pioneer in computational drug target discovery powered by AI/ML"

AI/ML stands for artificial intelligence and machine learning, software systems that identify patterns in data and make predictions or automate decisions, improving performance as they process more information. Investors care because these technologies can boost revenue, cut costs and create competitive advantages — like a factory that learns to produce goods faster and with fewer mistakes — while also introducing execution, ethical and regulatory risks that can affect a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link.

Following the live webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Currently, the only clinical trial we sponsor and are conducting is a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that we sponsor and are conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Contact:
Investor relations
Email: ir@cgen.com
Tel: +1 (628) 241-0071 

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-first-quarter-2026-results-on-monday-may-18-2026-302761152.html

SOURCE Compugen Ltd.

FAQ

When will Compugen (CGEN) release Q1 2026 results and when is the conference call?

Compugen will release Q1 2026 results on Monday, May 18, 2026 before U.S. markets open. According to the company, management will host a conference call and webcast to review results and provide a corporate update at 8:30 AM ET the same day.

How can investors join the Compugen (CGEN) earnings call on May 18, 2026?

Investors can join the Compugen earnings call by telephone or webcast. According to the company, dial 1-866-744-5399 (U.S.) or +972-3-918-0644 (international), or access the live webcast on Compugen's investor website at the scheduled time.

Will a replay of the Compugen (CGEN) May 18, 2026 webcast be available?

Yes. According to the company, a replay of the live webcast will be available on Compugen's website after the call, allowing investors to review the presentation and corporate update at their convenience following the live event.

What topics will Compugen (CGEN) cover during the May 18, 2026 conference call?

The conference call will review first quarter 2026 financial results and provide a corporate update. According to the company, management intends to discuss results, program progress, and company developments relevant to investors during the webcast and call.

Where can I find the webcast link and dial-in details for Compugen (CGEN) May 18, 2026 event?

Dial-in and webcast details are available on Compugen's investor website. According to the company, the announcement lists telephone numbers and the live webcast link, with a replay posted after the event for later access.